指南与共识消化、代谢与肾脏急症

美国内科医师学会临床指南:门诊环境下使用药物治疗预防发作性偏头痛

Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians.
指南 / 共识 · Ann Intern Med · 2025-02-04
一句话结论美国内科医师学会(ACP)推荐门诊非妊娠成人发作性偏头痛预防首选单药治疗,3条推荐均为条件性强度、低确定性证据。

美国内科医师学会(ACP)针对门诊成人发作性偏头痛(定义为每月头痛1至14天)制定本临床指南。ACP基于系统评价(比较药物疗效与危害)、患者价值观与偏好及经济学证据,采用GRADE方法评价血管紧张素转换酶抑制剂(赖诺普利)、血管紧张素II受体阻滞剂(坎地沙坦、替米沙坦)、抗癫痫药(丙戊酸、托吡酯)、β受体阻滞剂(美托洛尔、普萘洛尔)、CGRP拮抗剂-吉泮类(阿托吉泮或瑞美吉泮)、CGRP单克隆抗体(依普奈珠单抗、依瑞奈尤单抗、瑞美吉泮?原文为fremanezumab、galcanezumab,中文:夫瑞奈珠单抗、加卡奈珠单抗)、SSRI/SNRI(氟西汀、文拉法辛)及三环类抗抑郁药(阿米替林)等干预。指南推荐临床医生对门诊非妊娠成人发作性偏头痛启动单药预防治疗,并给出初始治疗不耐受或应答不足时的替代方案。全部3条推荐均为条件性强度、低确定性证据。

要点

  • ACP推荐临床医生对门诊非妊娠成人发作性偏头痛(每月头痛1至14天)启动单药预防治疗(条件性推荐,低确定性证据)。
  • 若初始预防治疗不耐受或应答不足,ACP推荐替代方法(条件性推荐,低确定性证据)。
  • 全部3条ACP推荐均为条件性强度、低确定性证据。
  • 指南基于系统评价比较ACEI(赖诺普利)、ARB(坎地沙坦、替米沙坦)、抗癫痫药(丙戊酸、托吡酯)、β受体阻滞剂(美托洛尔、普萘洛尔)、CGRP拮抗剂-吉泮类(阿托吉泮或瑞美吉泮)、CGRP单克隆抗体(依普奈珠单抗、依瑞奈尤单抗、夫瑞奈珠单抗、加卡奈珠单抗)、SSRI/SNRI(氟西汀、文拉法辛)及三环类抗抑郁药(阿米替林)的疗效与危害。
  • 指南采用GRADE方法评价药物对偏头痛频率与持续时间、急性治疗用药天数、偏头痛相关急诊就诊频率、偏头痛相关残疾、生活质量与身体功能、因不良事件停药等结局的影响。

适用人群与场景

  • 门诊成人发作性偏头痛患者,定义为每月头痛1至14天。
  • 非妊娠成人。

诊断标准与关键阈值

  • 发作性偏头痛定义为每月头痛1至14天。

处置流程与药物剂量

  • ACP推荐临床医生对门诊非妊娠成人发作性偏头痛启动单药预防治疗(条件性推荐,低确定性证据)。
  • 若初始治疗不耐受或应答不足,ACP推荐替代方法(条件性推荐,低确定性证据)。

研究设计与关键结果

  • ACP基于系统评价比较上述药物预防发作性偏头痛的获益与危害、患者价值观与偏好及经济学证据制定推荐。
  • ACP采用GRADE方法分析药物对偏头痛频率与持续时间、急性治疗用药天数、偏头痛相关急诊就诊频率、偏头痛相关残疾、生活质量与身体功能、因不良事件停药等结局的影响。
  • 不良事件通过美国食品药品监督管理局(FDA)药物标签和符合条件的研究获取。
  • 全部3条ACP推荐均为条件性强度、低确定性证据。

证据类型、等级与局限

  • 证据类型:临床指南;采用GRADE方法进行证据分级;全部3条推荐均为条件性强度、低确定性证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 临床医生可考虑对门诊非妊娠成人发作性偏头痛启动单药预防治疗(条件性推荐,低确定性证据)。
  • 若初始预防治疗不耐受或应答不足,可考虑替代方法(条件性推荐,低确定性证据)。

指南或共识出处

  • 美国内科医师学会(ACP)临床指南:Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings,发表于Annals of Internal Medicine。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

DESCRIPTION: The American College of Physicians (ACP) developed this clinical guideline for clinicians caring for adults with episodic migraine headache (defined as 1 to 14 headache days per month) in outpatient settings.

METHODS: ACP based these recommendations on systematic reviews of the comparative benefits and harms of pharmacologic treatments to prevent episodic migraine, patients' values and preferences, and economic evidence. ACP evaluated the comparative effectiveness of the following interventions: angiotensin-converting enzyme inhibitors (lisinopril), angiotensin II-receptor blockers (candesartan and telmisartan), antiseizure medications (valproate and topiramate), β-blockers (metoprolol and propranolol), calcitonin gene-related peptide (CGRP) antagonist-gepants (atogepant or rimegepant), CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, or galcanezumab), selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors (fluoxetine and venlafaxine), and a tricyclic antidepressant (amitriptyline). ACP used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to analyze the effects of pharmacologic treatment on the following outcomes: migraine frequency and duration, number of days medication was taken for acute treatment of migraine, frequency of migraine-related emergency department visits, migraine-related disability, quality of life and physical functioning, and discontinuations due to adverse events. In addition, adverse events were captured through U.S. Food and Drug Administration medication labels and eligible studies.

RECOMMENDATIONS: In this guideline, ACP makes recommendations for clinicians to initiate monotherapy for episodic migraine prevention in nonpregnant adults in the outpatient setting as well as alternative approaches if initial treatments are not tolerated or result in an inadequate response. All 3 ACP recommendations have conditional strength and low-certainty evidence. Clinical considerations provide additional context for physicians and other clinicians.

来源:Ann Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2025. PMID: 39899861. doi:10.7326/ANNALS-24-01052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。